NCT07426484 2026-02-23
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Dana-Farber Cancer Institute
Phase 4 Not yet recruiting
Dana-Farber Cancer Institute
Case Comprehensive Cancer Center
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
University Hospital, Toulouse